
Can I Delete My 23andMe DNA? Everything to Know as the Genetics Company Gets a New Owner
Smith Collection/Gado/Getty Images
Capping off a dire run of bad news in the last year, 23andMe announced last week that it will be acquired, in a new twist, by a nonprofit called TTAM Research Institute led by 23andMe co-founder Anne Wojcicki. Even with that resolution, the ordeals that the genetic-testing firm has weathered still may have a lot of folks wondering: Can I delete the genetic info that I sent to company? And how exactly can I go about doing that?
As we grow increasingly aware of how much of our personal information is gathered across the internet, our genetic information is perhaps the most personal data we could possibly share with anyone, especially commercial ventures. But over 15 million people did just that with 23andMe because of the ancestry-tracking services it offered.
These concerns certainly weren't soothed by recent news out of the company. In November, 23andMe announced it would lay off around 40% of its workforce in the wake of a major data leak and ongoing financial and management struggles, including a stock price that plummeted by 70%. Around 6.9 million customers were affected by the data breach, with investigations finding that the hackers responsible for the attack specifically targeted the accounts of people with Chinese or Ashkenazi Jewish heritage, which they spread on the dark web.
After all of that, and four years of dwindling sales, 23andMe entered bankruptcy proceedings. At first, a buyer for the company looked to be a pharmaceutical company, Regeneron, which stirred concerns about how the genetic data might be used. Then, in June, in a final round of bidding, TTAM got the green light to acquire 23andMe for $305 million (compared with Regeneron's $256 million offer). "I am thrilled that TTAM Research Institute will be able to continue the mission of 23andMe to help people access, understand and benefit from the human genome," Wojcicki said in a statement.
That may not be enough to satisfy privacy-conscious people out there. To get all the details about what you can do with the data 23andMe has from you, keep reading, and for more, find out how much 23andMe will pay out in a class-action settlement and read about the complex relationship between DNA testing companies and privacy. You can also check out CNET's Best DNA Testing services of 2025 list.
Can you delete your 23andMe account?
Yes. If you used 23andMe for DNA testing, you have the option to delete your account and personal information whenever you choose. A 23andMe spokesperson told CNET that once your request is submitted, the process of deleting data begins "immediately and automatically" and can take about 30 days to complete. But not all your data is deleted in 30 days.
In its June 13 press release announcing its acquisition, TTAM said it "will honor 23andMe's existing policies that allow individuals to delete their account and genetic data and opt out of research in perpetuity." It also said all customers will receive an email with details about TTAM's privacy policies and "instructions on how to delete data or opt out of research."
What data is deleted after you close your 23andMe account?
The answer to this is more complicated. Your 23andMe data will be deleted after you request the deletion of your profile, a company spokesperson told CNET. The process gives you the option to have the company discard your genetic sample, too, if you initially requested that 23andMe store it. And your information will no longer be usable for any of the company's research projects.
However, there's more to it than that.
"If a customer opted in to 23andMe Research, their Personal Information will no longer be used in any future research projects," the spokesperson said. "Please note, data cannot be removed from research that's already been conducted."
Bay Area news site SFGate found that genotyping laboratories that worked on a 23andMe customer's sample will also hold on to the customer's sex, date of birth and genetic information, even after they're "deleted."
A 23andMe representative said that by law, labs are required to retain the information for a set period of time -- from two to three years -- after which it will be deleted. The representative also said that this data is retained only by the genotyping lab, not 23andMe itself. If the lab were to be the subject of any sort of breach, the data it retains is anonymous -- it doesn't include a name, address, email, phone number or other contact information -- and the genetic information included is raw and unprocessed.
Before you delete your 23andMe account, download your data
Before closing your account, consider saving all your 23andMe information first, including your raw genotyping data, your DNA relatives and your ancestry composition. Some of the files can take up to 30 days to prepare, so make a plan for how you want to approach this.
Downloading your raw DNA file will let you upload your genetic data to another service for family or ethnicity searches, if you want.
Here's how to download your raw genotyping data and related information:
Log into your 23andMe account.
Head to Settings and in a browser scroll to the bottom and tap View next to 23andMe Data. In the app, scroll to the bottom of Settings and tap Access your data under 23andMe data.
Here, you can select which information you want to download before you delete your account. This includes an overview of your 23andMe reports, your ancestry composition raw data, your family tree data and your raw genetic data.
Note: These files come through as PDF, TXT, JSON and other formats, and you'll need the appropriate apps to view the data. For your DNA file, 23andMe will send you an email with a link you use to download the data.
You can also recreate everything in spreadsheets, as mapped out here, or take screenshots of everything. Some of the downloads come through right away, but some can take 30 days, 23andMe said.
How to delete your 23andMe account and data
Once you delete your data from 23andMe, unless you've downloaded it first, it's gone, the company warns. Ready? Here's how to delete your data:
Head to Settings again, scroll down to 23andMe Data, and tap View. You may be asked to verify your birthdate to continue.
If you've already downloaded or otherwise captured all the information you want to keep, scroll to the bottom and tap the Permanently Delete Data button.
23andMe will send you an email asking you to confirm your request. Once you do, the company will begin the deletion process and you will lose access to your account. If you had the company store your genetic samples, it will discard them.
For more, find out how 23andMe fares against its main competitor, Ancestry.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
BMO Favors MongoDB (MDB) for Non-Relational Database Strength, Sets $280 Target
MongoDB Inc. (NASDAQ:MDB) is one of the best large-cap tech stocks to buy now. Although MongoDB's core strength as a modern, document-based database and cloud data platform is still intact, it has been facing growth headwinds recently, especially since the results for the fourth quarter of FY 2025 (FY ends in January), when it provided a weaker guidance. Its Q1 2026 results, reported on June 4, were a tad better. The company is aiming to secure larger enterprise deals, but questions around the durability of its growth trajectory persist. That said, on July 28, BMO Capital's Keith Bachman began coverage on MongoDB with an Outperform rating and a $280 price target. He views the company as a clear leader in the fast-expanding non-relational database market, underpinned by substantial technology advantages. A database administrator managing a large database, ensuring the client's data is secure. Bachman also believes that the company's potential to capitalize on the growing demand for generative AI workloads and applications could contribute meaningfully to the company's growth in the coming years. This long-term positioning supports his constructive opinion on the stock despite near-term uncertainty. MongoDB Inc. (NASDAQ:MDB) develops database software and provides database platforms for automating, monitoring, and deploying data. While we acknowledge the potential of MDB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 10 Most Oversold Semiconductor Stocks So Far in 2025. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Analog Devices (ADI) Sees Bullish Sentiment Backed by Sector Tailwinds
Analog Devices Inc. (NASDAQ:ADI) is one of the best large-cap tech stocks to buy now. In mid-July, Tore Svanberg, an analyst at Stifel Nicolaus, raised his price target on Analog Devices to $270 from $248 while reiterating a Buy rating. In his view, the prolonged inventory correction across the semiconductor sector over the past two years has likely reached its trough, setting the stage for a cyclical rebound. However, it is difficult to gauge how quickly the rebound will unfold. Within this report, Svanberg also communicated his broader sector outlook, which continues to favour AI-linked semiconductor names. He expects the AI-focused companies under his coverage to post median revenue growth of 32% in 2025 and 17% in 2026, thus underscoring the structural demand tailwinds in this space. Within that context, Analog Devices is seen as well-positioned to benefit from the upturn, supporting the case for maintaining an overweight stance in AI-driven chipmakers. On July 25, Christopher Danely from Citi had also published his latest report, where he maintained a Buy rating on Analog Devices, with a price target of $290. While analysts remain confident in the company, it is worth noting the positive perspective shared by Kovitz Investment Group Partners in its Q2 2025 'Kovitz Core Equity Strategy' investor letter. The firm cited several reasons for its long-term optimism on Analog Devices, including its leadership in key markets, robust 70% gross margins that help offset tariff impacts, and an irreplaceable talent pool of 11,000 experienced analog engineers. With the stock currently at an appealing valuation, Kovitz's portfolio managers believe that it offers a compelling opportunity for investors over the next five to seven years. The company is expected to report its Q3 2025 results on August 20. Analog Devices Inc. (NASDAQ:ADI) is a semiconductor company that designs, manufactures, tests, and markets a broad portfolio of solutions using high-performance analog, mixed-signal, and digital signal processing technologies. While we acknowledge the potential of ADI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 10 Most Oversold Semiconductor Stocks So Far in 2025. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
CoreWeave's AI Demand Surges But Expansion Spending Cuts Into Profitability
CoreWeave (NASDAQ:CRWV) shares tumbled on Wednesday after the AI-focused cloud computing provider posted mixed second-quarter results, highlighting surging revenue and backlog alongside margin pressures from an aggressive expansion plan. The company reported $1.21 billion in quarterly revenue, well above prior-year levels and fueled by new contracts with OpenAI and major hyperscalers, but investors reacted to guidance that signals significant near-term costs as CoreWeave ramps capacity toward 900MW by year-end. Stifel analyst Ruben Roy maintained a Hold rating on the stock, raising his price forecast to $120 from $115. HC Wainwright's Kevin Dede kept a Neutral rating, while Needham analyst Mike Cikos also maintained a Highlights Backlog and Revenue Strength Roy said CoreWeave delivered strong second-quarter results, surpassing revenue and adjusted operating income estimates on continued compute demand despite power constraints. He noted that the backlog rose to about $30.1 billion, bolstered by a $4 billion OpenAI expansion and new hyperscaler contract wins likely tied to Microsoft (NASDAQ:MSFT), Meta Platforms (NASDAQ:META), and/or Alphabet (NASDAQ:GOOGL) Google. Another expansion is set to benefit the third quarter. Roy called guidance 'mixed,' with third-quarter and full-year 2025 revenue outlooks above consensus but margins below expectations due to management conservatism. He projected third-quarter revenue of $1.28 billion and full-year 2025 revenue of $5.25 billion, alongside adjusted operating income of $175 million for the third quarter and $815 million for the year. His model factors elevated interest expense from recent debt raises, reaffirmed a $21.5 billion fiscal 2025 CapEx target to reach 900MW capacity, and potential ~10% dilution from the pending Core Scientific (NASDAQ:CORZ) acquisition. HC Wainwright Notes Blockbuster Q2 Performance Dede said CoreWeave delivered a 'blockbuster' second quarter, with revenue climbing 23.5% sequentially to $1.213 billion, well above his $1.063 billion forecast, driven by AI adoption across consumer and enterprise markets. He pointed to a 16% sequential jump in backlog to $30.1 billion, fueled by a $4 billion OpenAI extension and a new hyperscaler deal. He noted that CoreWeave expects to expand capacity from 470MW to 900MW by year-end, with 2.2GW contracted. Dede raised his fiscal 2025 sales estimate to $5.154 billion from $4.942 billion, reflecting $150 million in second-quarter outperformance and management's 4%–7% sequential growth guidance for the third quarter. He kept his fiscal 2026 forecast at $11.2 billion. He noted AI integration becoming mandatory for competitive enterprises and highlighted CoreWeave's new wins with Morgan Stanley (NYSE:MS) and Goldman Sachs (NYSE:GS). Needham Emphasizes Backlog and Capacity Buildout Cikos said CoreWeave delivered a second straight quarter of substantial upside, beating his second-quarter revenue estimate of $1.09 billion with $1.21 billion and exceeding his adjusted operating income forecast of $163.6 million with $199.8 million. Management guided third-quarter revenue 2% above Street expectations at the midpoint. In contrast, full-year revenue guidance of $5.15 billion to $5.35 billion raised the midpoint by $250 million, well above the second-quarter beat of about $130 million. Cikos noted management's plan to exit 2025 with more than 900MW of active power, up roughly 90% from the second quarter's 470MW, with capital expenditures of $20 billion to $23 billion serving as a strong leading indicator for future revenue but a near-term margin headwind. He highlighted the growing backlog, up 86% year-over-year to $30.1 billion, supported by the $11.9 billion OpenAI deal, a $4 billion OpenAI expansion, and another hyperscaler contract to be reflected in third-quarter results. Cikos projected fiscal 2025 revenue of $5.1 billion and adjusted operating income of $821 million, and he flagged execution and supplier risks tied to the significant capacity buildout. Price Actions: CRWV stock is trading lower by 18.92% to $120.61 at last check Wednesday. Photo by JackPress via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? COREWEAVE (CRWV): Free Stock Analysis Report This article CoreWeave's AI Demand Surges But Expansion Spending Cuts Into Profitability originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.